Prostaglandins are critical mediators of a variety of physiological processes ranging from platelet aggregation and vasoconstriction to inflammation. The initial step in the biosynthesis of these bioactive lipids is accomplished by prostaglandin endoperoxide synthase (PGHS) 3 . This heme-containing enzyme catalyzes the incorporation of two molecules of dioxygen into arachidonic acid to form the hydroperoxy endoperoxide (PGG 2 ) and the reduction of PGG 2 to the corresponding hydroxy endoperoxide (PGH 2 ) (Scheme I) (1, 2) . Once formed, PGH 2 is converted by different enzymes to produce prostaglandins and thromboxane (again see Scheme I) (3, 4) . The reactions catalyzed by PGHS occur at two biochemically and structurally distinct sites in PGHS termed the cyclooxygenase and peroxidase active sites, respectively. Although the active sites are separate, the heme prosthetic group is absolutely required for both activities (5) . X-ray analysis indicates that it is interposed between the two active sites (6 -8) .
Recently, it has been demonstrated that there are two isoforms of PGHS, each of which catalyzes the cyclooxygenase and peroxidase reactions (9, 10) . PGHS-1 is constitutively expressed in a variety of cells such as gastrointestinal epithelial cells and platelets. In these cells, PGH 2 is processed to prostaglandins critical for gastric cytoprotection and to thromboxane A 2 , which is a powerful stimulus for platelet aggregation (3, 4, 11) . Conversely, PGHS-2 is an inducible enzyme expressed transiently in a variety of cells including fibroblasts, macrophages, endothelial cells, vascular smooth muscle cells, neurons, and astrocytes in response to pathophysiological challenge (1, 3, 4, 12) . For example, PGHS-2 is a critical player in the propagation of the inflammatory response.
Like prostaglandins, nitric oxide (NO .
) has been implicated in a wide variety of physiological processes including vasodilation, neurotransmission, and inflammation (13) (14) (15) . NO . also is generated by constitutive and inducible enzymes. As with PGHS, inducible nitric oxide synthase (iNOS) is associated primarily with inflammation and other immunological processes (13, 14) .
The inflammatory response involves the production of highly reactive compounds including O 2 .Ϫ , NO . , ONOO Ϫ , H 2 O 2 , and HOCl. Although these compounds and the processes responsible for their generation are necessary for successful defense against foreign invaders, their production also results in 'collateral damage' to host tissue components, including proteins, lipids/membranes, and DNA. Therefore, it is not surprising to find an association between sustained or chronic inflammation and development of autoimmune disease, cardiovascular disease, and cancer (3, 4, 16 -19) . Inhibitors of both PGHS and nitric oxide synthase (NOS) have shown promise not only as antiinflammatory agents, but also as cancer preventive agents (3, 4, 15, 19) .
Although both NO
. and prostaglandins are involved in inflammation and related diseases, only recently have investigations suggested a direct link between NO
. production and synthesis of prostaglandins by PGHS. In the long run, such an interaction may prove to be an additional point of manipulation of the inflammatory response to prevent the development of a range of debilitating illnesses.
NO . AND PROSTAGLANDIN BIOSYNTHESIS
It is well established that stimulation of a wide variety of cell types with cytokines and other messengers results in the rapid induction of iNOS and PGHS (20 -28) . Several investigators have also demonstrated that in cells expressing both inducible PGHS and NOS, NO . potentiates the formation of prostaglandins. Salvemini and co-workers (29) have shown that addition of the NOS inhibitors N G -monomethyl-L-arginine (L-NMMA) or aminoguanidine to lipopolysaccharide (LPS) -stimulated mouse macrophages (RAW 264.7) results not only in a decrease in nitrite formation, but also a four-to fivefold decrease in prostaglandin E 2 (PGE 2 ) biosynthesis. Conversely, the addition of the PGHS inhibitor indomethacin only inhibits PGE 2 synthesis, and not nitrite formation.
Modulation of NOS substrate levels also affects prostaglandin biosynthesis in this macrophage system. Inhibition of PGE 2 and nitrite formation by L-NMMA or aminoguanidine is reversed by the addition of L-but not D-arginine (29) . Furthermore, when macrophages are grown on L-arginine-deficient media, they do not produce nitrite, and PGE 2 synthesis is decreased fivefold upon LPS stimulation compared with cells grown in complete medium. As above, addition of L-arginine restores full NO . biosynthesis and PGHS activities, but D-arginine has no effect. In a similar manner, addition of NO . as an NO . -saturated solution or generation of NO . from a donor (e.g., sodium nitroprusside [SNP]) fully restores PGE 2 biosynthesis. PGHS activity restored by L-arginine addition is sensitive to NOS inhibitors, but these same inhibitors have no effect when activity is restored using NO . or NO . donor molecules (29 ; methylene blue, an inhibitor of sGC. PGE 2 synthesis, is blocked only by hemoglobin, not methylene blue (29) . This suggests that the effect of NO . on prostaglandin synthesis is cGMP independent. Similarly, using RAW267.4 cells, Eling and others (30) have demonstrated that NO . from several different sources does not increase either PGHS-2 mRNA or protein levels ( Fig. 1) , eliminating transcriptional control as a mechanism for NO . -stimulated prostaglandin biosynthesis in these cells.
The ability of NO . to enhance prostaglandin biosynthesis has been observed in other cell culture and in vivo models. These include various rat tissues (21, (31) (32) (33) (34) , bovine endothelial cells (21, 27) , human airway epithelial cells (A459) (35) , and a rabbit renal inflammation model (36) . Likewise, McDaniel and others (20) report the enhancement of prostaglandin biosynthesis by NO . in rat islets of Langerhans and propose that interaction between PGHS and NO . may play a role development of autoimmune diabetes.
The administration of LPS to rats results in the expression of both iNOS and PGHS-2, with concomitant development of cerebral hyperemia. Consistent with the proposed direct activation of PGHS by NO . , Okamoto and others (28) note that NO . enhances PGHS-2 activity without significantly changing PGHS-2 protein levels. In a recent study, Iadecola (37) observed similar results in a cerebral ischemia model. It is striking that administration of aminoguanidine inhibits PGE 2 biosynthesis only in the area of cerebral infarct, and not in unaffected areas of the brain such as the olfactory bulb. This correlates with the recruitment of neutrophils expressing iNOS to the area of cerebral injury. Furthermore, ischemia-induced PGE 2 biosynthesis is significantly reduced in iNOS knockout mice compared with wild-type animals. PGHS-2 expression induced by cerebral injury is not diminished in the iNOS null mice (37) , further indicating a direct interaction between the PGHS protein and NO . . Although many studies indicate that NO . directly interacts with PGHS to stimulate prostaglandin production, some have suggested that this phenomenon may result (at least in part) from an effect of NO . on transcription of the PGHS-2 gene. Tetsuka et al. (23) and Watkins et al. (35) suggest that this transcriptional effect is mediated through a cGMP-dependent mechanism in rat mesangial cells and human lung epithelial (A459) cells, respectively. Hughes et al. (22) has a profound effect on PGHS-2 expression in interferon-␥-stimulated osteoblasts, whereas the same cells stimulated with IL-1␤ are relatively insensitive to NO . (22) . The inhibition of PGHS-2 expression by NO . has been observed in mouse (J774.2) and rat macrophages and chondrocytes from osteoarthritic patients. In these studies, NOS inhibitors act to increase PGHS-2 expression and prostaglandin biosynthesis in response to cytokine stimulation (24, 25, 38) , and the addition of NO . donors reverse this effect (24, 25) . In addition to inhibition of PGHS-2 expression by NO . , Swierkosz et al. (25) Some suggest that there is no interaction between NO . synthesis and prostaglandin biosynthesis. Hamilton and Warner observed that the selective iNOS inhibitor 1400W had no effect on prostaglandin production in a rat platelet aggregation model (41) . They suggest that the supposed link between iNOS and PGHS-2 activity results from the inability of NOS inhibitors to block iNOS specifically. However, these authors observed the same result with a nonselective NOS inhibitor (41) .
It is clear that a large group of investigators have observed NO .
-stimulated prostaglandin biosynthesis, apparently by direct interaction with PGHS; however, the field is by no means unified regarding the relationship between NO . and prostaglandin biosynthesis. Matters are not helped by the fact that NO . does not consistently enhance or inhibit prostanoid biosynthesis across cellular or in vivo models. This is compounded by the complexity arising from NO . effects on transcription, post-transcriptional processing, translation, posttranslational processing, or PGHS catalysis. This wide variability in observations may result from the use of differing cell lines and tissues, as well as differences in methods of cell activation and NO . delivery. Of course, more investigation will also be necessary in order to evaluate the number of possible interactions that might take place between the NO . and prostanoid biosynthetic pathways. These include, but are not limited to: 1) downstream enzymes such as PGE isomerase, prostacyclin synthase, thromboxane synthase, 2) other arachidonate metabolizing enzymes such as lipoxygenase and cytochromes P450, and 3) transcriptional regulation of these enzymes by NO . .
INTERACTIONS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE WITH NO .
Given the stimulation of prostaglandin biosynthesis by NO . in many cellular and in vivo models as well as the conflicting observations suggesting other interactions between these pathways, it is of great interest to determine the nature of the interaction between NO . and the PGHS protein. Several in vitro studies have been undertaken to address this issue; however, the results of these investigations have also varied widely. Some investigators note that NO . stimulates prostaglandin synthesis by PGHS (42, 43) . Others observe either no stimulation or slight inhibition of the enzyme by NO . (30, 44, 45) . In light of the conflicting findings, several possible mechanisms of NO . /PGHS interaction are discussed along with the evidence for and/or against each interaction as a mechanistic explanation for NO . -enhanced arachidonate oxygenation by PGHS in vivo.
Heme iron coordination
It is well established that NO . binds efficiently to many iron-containing proteins including cis-aconitase, NADH-ubiquinone oxidoreductase, lipoxygenase, and most heme proteins (13, 14, (45) (46) (47) (48) . Indeed, the first established receptor for NO . in vivo is the heme-containing protein sGC (49 -51) . Thus, a reasonable hypothesis is that an interaction between the PGHS heme and NO
. results in activation of the enzyme. Kulmacz and others have established that NO . does bind to PGHS heme in its ferric (native) form (44) . The spectral shifts observed upon NO . binding ( Fig. 2A) (Fig. 2B) , indicating that the heme is displaced from its proximal histidine ligand (44, 48) . In this way, Fe II PGHS behaves more like Fe II sGC than Fe II myoglobin, hemoglobin, or horseradish peroxidase (48, 53) . NO . does not displace the proximal ligand in these proteins. Instead, a sixcoordinate, low-spin Fe II -NO complex with a Soret maximum near 420 nm is observed (44, 48, 53 . binding to sGC activates the enzyme, the metal center does not participate in the catalytic reaction. In contrast, the ferric heme of PGHS undergoes oxidation to a ferryl-oxo form, which then oxidizes Tyr385 to a tyrosyl radical that oxidizes arachidonic acid (60 -64) . There is no apparent role for the ferrous enzyme, and if it did form, coupling to NO . would result in heme dissociation and the loss of cyclooxygenase activity. Thus, it seems unlikely that the Fe II -NO complex of PGHS forms in vivo or that its formation results in the activation of the enzyme.
As the spectroscopic and kinetic parameters of NO . binding suggest, Kulmacz and co-workers (44) observed that NO . has little effect on cyclooxygenase activity in vitro. At concentrations of NO . exceeding 1 mM, these authors detected no increase in PGHS activity. In fact, only slight inhibition was observed. These data would indicate that NO . does not enhance PGHS activity by coordination to the heme iron or by any other mechanism.
NO . interaction with PGHS thiols
In one respect, the work of Hajjar et al. (42) confirms the findings of Kulmacz and colleagues (44) . They note that NO . does not stimulate PGHS turnover through an interaction with the heme prosthetic group. However, these authors and others have observed the apparent stimulation of purified 
PGHS-1 in vitro by NO
. (42, 43) . In their hands, this stimulatory effect (about fourfold) is similar to that reported by Salvemini and co-workers in RAW 264.7 cells (29 produces no dramatic shift in the PGHS heme absorption spectrum; however, substantial changes in the far-UV CD spectrum of PGHS are detected. Indeed, a 40% increase in ␤ sheet structure is calculated (42) .
Because cysteine 512 is not conserved between PGHS-1 and PGHS-2 (6 -8, 65), it is unlikely that modification of this residue is responsible for the PGHS activation observed in various cellular models. However, both cysteine 313 and cysteine 540 (Fig. 3) are conserved between all known PGHS-1 and PGHS-2 sequences (65). Furthermore, it has been shown that modification of cysteines 313 and 540 by either chemical means (maleimides) (66) 
complete inactivation of PGHS, even with the conservative substitution of serine for cysteine. With this in mind, it is difficult to envision how nitrosylation of these residues by an oxidation product of NO . along with the apparent dramatic structural changes could result in PGHS activation instead of inactivation.
NO . as a tyrosyl radical trap
Another reaction commonly observed with NO . is the one with phenoxyl radicals to form the corresponding O-nitrosophenol (reaction 1) or nitrosocyclohexadienone (reaction 2) products. This reaction is observed not only with small phenolic compounds but also with proteins bearing tyrosyl radicals (68 -73) . Indeed, NO
. reacts rapidly with ribonucleotide reductase, silencing its EPR tyrosyl radical signal and blocking enzymatic activity (72, 73) . The reaction is reversible in that removal of NO . results in restoration of the tyrosyl radical and enzymatic activity (72, 73) .
PGHS also produces a tyrosyl radical critical to its catalytic mechanism. Unlike ribonucleotide reductase, the tyrosyl radical is not detected with resting enzyme. Instead, this radical must be formed by the transfer of an electron from a tyrosine in the cyclooxygenase active site to the heme prosthetic group of the enzyme (61, 62) . This two-step process, called cyclooxygenase activation, is carried out by the peroxidase activity of PGHS. First, the heme prosthetic group is oxidized by a hydroperoxide by two electrons from its Fe III form to a ferryloxo porphyrin cation radical derivative (reaction 3). The porphyrin radical is then reduced to its fully covalent form by an electron taken from a tyrosine residue (reaction 4). The resulting tyrosyl radical is an integral player in the 
͓Y]Fe
proposed catalytic mechanism for prostaglandin biosynthesis (Scheme II). Since a hydroperoxide (PGG 2 ) is produced as a result of cyclooxygenase turnover, only nanomolar starting concentrations of fatty acid hydroperoxide are required to achieve full activation of PGHS (74) . Contaminating peroxides in preparations of arachidonic acid are sufficient to achieve full activation of PGHS. Indeed, incubation of PGHS with arachidonic acid results in the formation of a tyrosyl radical detectable by EPR spectroscopy (61). Similar to ribonucleotide reductase, the PGHS tyrosyl radical reacts rapidly with NO . ; however, instead of forming a reversible adduct, the initial nitrosocyclohexadiene-one product is oxidized further. Indeed, Gunther et al. (75) have observed an iminoxyl radical upon incubation of PGHS-2 with its substrate, arachidonate, and NO . (Fig. 4A) . This radical decays with time to an EPR silent intermediate. Both Western blotting and peptide mapping studies indicate that the final product of the reaction is nitrotyrosine (75, 76) . This suggests that upon reaction between NO . and the PGHS tyrosyl radical, the cyclohexadienone adduct is oxidized further, first to the iminoxyl radical intermediate and finally to nitrotyrosine (Scheme III). Oxidation of the initial nitrosocyclohexadienone adduct appears to occur as a result of the peroxidase activity of PGHS (75) . Substitution of the normal Fe III protoporphyrin IX prosthetic group of PGHS with the Mn III derivative produces an enzyme with full cyclooxygenase activity, but only 0.8% peroxidase activity (5, 77-79). As Fig. 4B indicates, this substitution results in an impeded rate of iminoxyl radical formation and decay.
Given the necessity for a tyrosyl radical in the mechanism of arachidonate oxygenation by PGHS, reaction between NO . and this tyrosyl radical would tend to indicate an inhibitory effect on PGHS activity, especially considering the stability and relative difficulty of oxidizing a nitrated aromatic ring.
Scheme II. Mechanism of PGHS catalysis indicating the generation of a PGHS tyrosyl radical and its role in arachidonate oxygenation.
Therefore, it is unlikely that the observed activation of PGHS in vivo by NO . is the result of this particular interaction. In fact, it is surprising that NO . is not a strong inhibitor of cyclooxygenase activity.
This particular oddity may be resolved by noting that NO . acts as a potent reducing substrate for the peroxidase activity of PGHS (30) , and as such should dramatically stimulate arachidonate oxygenation (80) . More than one group has observed that NO . is a slight inhibitor of the enzyme at high concentrations (30, 44) . It may be that stimulatory effects expected from NO . as a reducing substrate are counteracted by its role as a tyrosyl radical trap. Also, like most trapping reactions, NO
. reaction with tyrosyl radical and the subsequent conversion of the adduct to nitrotyrosine may not be efficient, especially considering the relatively low concentrations of NO . compared with many spin trapping protocols. Finally, in the presence of high concentrations of arachidonate (i.e., 100 -500 ϫ K m ), NO . may not compete as effectively for the PGHS tyrosyl radical.
Identification of PGHS tyrosyl radicals
Although nitration of PGHS tyrosines in the presence of NO . and arachidonic acid may not explain NO . activation of PGHS in vivo, this unique interaction proved helpful in resolving a longstanding issue regarding the mechanism of activation of PGHS: identification of the tyrosine oxidized to a radical during cyclooxygenase catalysis. Smith and co-workers demonstrated by site-directed mutagenesis that Tyr385 is essential to cyclooxygenase activity (63, 81, 82) . Although the Tyr385Phe mutant lacks cyclooxygenase activity, reaction of this protein with a peroxide leads to the formation of a spectroscopically detectable tyrosyl radical (81) (82) (83) . Also puzzling is the fact that the PGHS mutant, His386Ala, fails to produce a tyrosyl radical detectable by EPR, yet this protein retains significant cyclooxygenase activity (1, 65) . Thus, it has been difficult to conclude unequivocally that Tyr385 is in fact oxidized to a radical intermediate during cyclooxygenase catalysis. Likewise, it has been difficult to conclude that the tyrosyl radical observed by EPR is essential to the cyclooxygenase mechanism.
The reaction between PGHS tyrosyl radical and NO . combined with the stability and unique absorption spectrum of nitrotyrosine (the final product of the reaction) provided for a new approach to identify the tyrosine oxidized during cyclooxygenase turnover. We investigated by peptide mapping and subsequent amino acid sequence analysis that PGHS tyrosines are nitrated in the presence of NO . and arachidonic acid, and observed that only Tyr385 is nitrated (Fig. 5) (76) . Along with the results of Tyr385 mutagenesis (63, 81, 82) , these data provide strong support for the proposed mechanism of PGHS cyclooxygenase activation and sustained turnover, as well as the central role for Tyr385 in cyclooxygenase catalysis.
Tsai and co-workers (64), using an elegant combination of site-directed mutagenesis and EPR spectroscopy, have also shown that Tyr385 is oxidized to a radical intermediate, and this radical is uniquely able to oxidize arachidonate. As established previously, tyrosyl radicals are detected with both wildtype and Tyr385Phe PGHS (81) (82) (83) ; however, these investigators have shown that only the radical detected with the wild-type protein is able to abstract a hydrogen from arachidonic acid to initiate the cyclooxygenase catalytic cycle. Clearly, the PGHS tyrosyl radical is centered on Tyr385, and this radical is essential for PGHS catalysis. 
PEROXYNITRITE AND PGHS

In numerous in vivo and cellular systems, NO
. has a stimulatory effect on prostaglandin biosynthesis that appears to be the result of direct interaction between NO . and PGHS. However, NO . itself appears to have no clear effect on the ability of purified PGHS to oxygenate arachidonic acid. Indeed, most possible interactions between NO . and PGHS are more likely to result in inhibition rather than activation. One possible explanation for the disparity between the results of these investigations is that NO . is only a precursor to the activating molecule. Under these circumstances, one would expect that the other components necessary to accomplish activation may be present in the cellular systems, but are absent in simplified experiments where NO
. is added to purified PGHS.
Peroxynitrite as a peroxidase substrate
Much of the work demonstrating a link between NO . and prostaglandins has been undertaken using inflammation models where neutrophils or macrophages are involved. In addition to producing NO . , these cells produce copious amounts of O 2 .Ϫ using an NADPH oxidase (84, 85) or NOS itself (86) Likewise, Fe III myelo-, lacto-, and horseradish peroxidases react with ONOO Ϫ at comparable rate constants to form ferryl-oxo complexes, most probably compound I (i.e., Fe IV ϭO[porphyrin radical]) (91) . Once formed, these reactive porphyrins (free and protein bound) rapidly oxidize reductants such as guaiacol, glutathione, trolox, and ascorbate to regenerate the Fe III porphyrin at rates at least three orders of magnitude higher than the direct reaction between ONOO Ϫ and these electron donors (88, 90, 92, 93) . This constitutes typical peroxidase activity where ONOO Ϫ acts as the peroxide source of oxidizing equivalents. As discussed, the peroxidase activity of PGHS is proposed to be critical to activation of the PGHS cyclooxygenase. That is, peroxides oxidize the PGHS heme prosthetic group, which then oxidizes Tyr385 to the tyrosyl radical intermediate that oxidizes arachidonic acid. Therefore, it is reasonable to suggest that ONOO Ϫ may activate cyclooxygenase catalysis as a typical peroxide substrate.
ONOO Ϫ supports PGHS-catalyzed guaiacol oxidation, and therefore is a substrate for PGHS peroxidase activity (94) . The PGHS peroxidase can use a wide variety of peroxides to support the oxidation of small organic reducing substrates (80, 95) , and the kinetic parameters for ONOO Ϫ reaction with PGHS are generally consistent with those observed for other hydroperoxides ( Table 1) . Although the K m of PGHS for peroxynitrite is considerably larger than that of the fatty acid hydroperoxide, 15-HPETE, it is lower than that of H 2 O 2 . Moreover, ONOO Ϫ supports a greater extent of guaiacol oxidation than either 15-HPETE or H 2 O 2 . Given the bolus method of addition and the rapid decomposition of ONOO Ϫ under the assay conditions used, these kinetic values should be taken as estimates.
Peroxynitrite, glutathione peroxidase, and PGHS activation
Peroxides are required to activate PGHS, and preparations of arachidonic acid contain sufficient quantities of fatty acid hydroperoxide impurities to accomplish full activation of cyclooxygenase. To block activation by these peroxides, PGHS must be placed in a reaction with high concentrations of glutathione/glutathione peroxidase (GSH/GPx) (74, 96, 97) . Any hydroperoxides present in the arachidonic acid are consumed and the cyclooxygenase remains inactive. Under these conditions, the ability of vari- (94) . b The units of k cat * are mol guaiacol oxidized per mol PGHS. The rates of guaiacol oxidation were determined over a range of peroxide concentrations and control assays were performed in the absence of enzyme to correct for nonenzymatic oxidation.
ous exogenously added hydroperoxides to accomplish activation can be evaluated. ONOO Ϫ is able to initiate cyclooxygenase turnover even in the presence of GSH/GPx (Fig. 6) .
Although reaction of ONOO
Ϫ with GSH can result in O 2 consumption independent of prostaglandin synthesis, most of the O 2 consumption observed in Fig. 6 is the result of arachidonate oxygenation, not GSH oxidation. This is confirmed by the fact that the majority of O 2 uptake is inhibited by the cyclooxygenase inhibitor indomethacin and that prostaglandin products are detected when ONOO Ϫ is added to PGHS and arachidonate in the presence of GSH/ GPx (94) donor and xanthine/xanthine oxidase reverses GSH/GPx inhibition of PGHS (Fig. 7) , but withholding either component prevents PGHS activation. Similarly, decomposition of SIN-1 (to produce both NO . and O 2 .-) in the presence of PGHS, GPx, up to 2.5 mM GSH, and arachidonate results in synthesis of prostaglandins (Fig. 8) would also retard prostaglandin biosynthesis. We have observed the dose-dependent inhibition of prostaglandins in activated RAW267.4 cells by two SOD mimetic agents, CuDIPS (Fig. 9) and MnTMPyP (94) .The extent of inhibition by these agents (about a 4 -5 fold decrease in PGD 2 and PGE 2 ) is similar to the effect observed upon removing NO . (29) . Furthermore, the parallel decrease in PGE 2 and PGD 2 suggests that the effect of the SOD mimics is not on the prostaglandin isomerases. Several control experiments indicate that the only effect of these compounds is the removal of O 2 .-: 1) neither CuDIPS nor MnTMPyP inhibits expression of NOS or PGHS-2, 2) they do not directly inhibit PGHS-1, PGHS-2, or NOS, and 3) neither appears to inhibit phospholipase A 2 because both CuDIPS and MnTMPyP inhibit prostaglandin synthesis whether arachidonate is derived from endogenous or exogenous sources. These results with SOD mimetic agents parallel the effects of Cu/Zn SOD upon cyclooxygenase activation by peroxynitrite in vitro with purified PGHS (see Fig. 9 ).
Based on these results, we propose that NO . enhances PGHS activity under inflammatory conditions by acting as a precursor to ONOO Ϫ , a potent peroxide activator of PGHS (Scheme IV). In response to inflammatory signals (e.g., LPS, cytokines, and other messengers), cells express iNOS and PGHS-2. Furthermore, inflammatory cells such as neutrophils and macrophages produce large quantities of O 2 .-using an NADPH oxidase. the roles of ONOO Ϫ and NO . in the production of prostaglandins. The kinetics of PGHS heme oxidation by ONOO Ϫ have received only cursory examination. This is critical as ONOO Ϫ has been shown to also react with GPx; thus, it is not entirely certain how sufficient ONOO Ϫ 'survives' to react with PGHS in the presence of GSH/GPx. This is an issue that may be resolved kinetically; therefore, detailed kinetic characterization of ONOO Ϫ reactions with GPx and PGHS is required. ONOO Ϫ has been reported to inactivate GPx (98 
